Report summary

Notifier

Name of person with notification obligation

Stefan Nilsson

Reason for notification

Closely associated

Person discharging managerial responsibilities

Stefan Nilsson

Position

Chief Executive Officer (CEO)/Managing Directory

Initial notification

Yes

Amendment

Details of amendment

Details of the Issuer/emission allowance market participant/auction platform/auctioneer/auction monitor

Name of issuer

Lipigon Pharmaceuticals AB

Issuer´s LEI code

549300XPO40YR12SLY87

Details of transaction

Type of financial instrument	Financial instrument	ISIN code	Nature of transaction	Linked to the exercise of a share option programme	Volume	Unit	Price per unit	Currency code	Transaction date	Place of the transaction
Subcription warrant	Lipigon Pharmaceuticals AB TO2	SE0019914094	Exercise decrease		10,500	Quantity	0.30	SEK	15/12/2023	Outside a trading venue
Share	Lipigon Pharmaceuticals AB	SE0015382072	Exercise increase		10,500	Quantity	0.30	SEK	15/12/2023	Outside a trading venue

Aggregation

Financial instrument	ISIN code	Nature of transaction	Transaction date	Place of the transaction	Volume	Weighted average price
Lipigon Pharmaceuticals AB TO2	SE0019914094	Exercise decrease	15/12/2023	Outside a trading venue	10,500 (Quantity)	0.30 SEK
Lipigon Pharmaceuticals AB	SE0015382072	Exercise increase	15/12/2023	Outside a trading venue	10,500 (Quantity)	0.30 SEK

<< Back